Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Overview of attention for article published in New England Journal of Medicine, August 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 31 news outlets
blogs: 5 blogs
policy: 1 policy source
twitter: 364 X users
facebook: 1 Facebook page
wikipedia: 4 Wikipedia pages

reddit: 2 Redditors
f1000: 1 research highlight platform
video: 1 YouTube creator
guideline: 9 clinical guideline sources
podcasts: 5 podcasts

Readers on

mendeley: 246 Mendeley

So far, Altmetric has seen 51 news stories from 31 outlets.

Längeres krankheitsfreies Überleben durch adjuvante Immuntherapie beim Nierenzellkarzinom – Deutsches Ärzteblatt

Deutsches Ärzteblatt, 06 Nov 2025

News Medizin Längeres krankheitsfreies Überleben durch adjuvante Immuntherapie beim Nierenzellkarzinom Medizin Donnerstag, 6.

Vacunas personalizadas contra el cáncer: un avance prometedor en el carcinoma de células renales

Gaceta Medica, 06 Feb 2025

Las vacunas personalizadas contra el cáncer (PCV, por sus siglas en inglés) tienen el potencial de inducir respuestas…

In Cancer Care, Innovation Comes at a Cost

AJMC, 14 Oct 2024

Cancer care is constantly evolving, with treatment armamentariums expanding and new data releases coming at an increasing pace.

GU 腫瘍学の仲間が低容量 mRCC の早期治療アプローチを模索 - nipponese.news - Nipponese

Nipponese.news, 19 Sep 2024

チャンドラーパーク、メリーランド州腫瘍内科医ノートンがん研究所顧問学部長/臨床教授ルイビル大学医学部ケンタッキー州ルイビルディスカッションの質問転移性腎細胞癌（mRCC）の患者のうち、左腎摘出および副腎摘出後に経過観察のみを必要とする低容量で進…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 47 additional news stories.